cross-neutralization four paramyxoviruses human monoclonal antibody 
broadly neutralizing antibodies reactive even variants viral species described influenza hiv ref however whether neutralizing antibody breadth range target different viral species unknown human respiratory syncytial virus hrsv human metapneumovirus hmpv common pathogens cause severe disease premature newborns hospitalized children immune-compromised patients play role asthma exacerbations although antisera generated either hrsv hmpv cross-neutralizing speculated repeated exposure viruses cross-neutralizing antibodies may selected individuals describe human monoclonal antibody mpe8 potently cross-neutralizes hrsv hmpv well two animal paramyxoviruses: bovine rsv brsv pneumonia virus mice pvm germline configuration mpe8 hrsv-specific breadth achieved somatic mutations light chain variable region mpe8 result selection viral escape mutants evaded antibody targeting showed potent prophylactic efficacy animal models hrsv hmpv infection well prophylactic therapeutic efficacy relevant model lethal pvm infection core epitope mpe8 mapped two highly conserved anti-parallel beta-strands pre-fusion viral f protein rearranged post-fusion f protein conformation twenty-six thirty hrsv-specific neutralizing antibodies isolated also found specific pre-fusion f protein taken together results indicate mpe8 might used prophylaxis therapy severe hrsv hmpv infections identify pre-fusion f protein candidate hrsv vaccine 
